RCKT secures $150M term loan facility from Hercules Capital

Rocket Pharmaceuticals entered a loan and security agreement with Hercules Capital on September 30, 2026, providing up to $150 million in senior secured term loans across five tranches, with $35 million funded immediately. This is material financing that extends RCKT's cash runway and provides access to capital tied to clinical milestones (Tranche 2 Milestone) and FDA approval of RP-A501 for Danon Disease (Approval Milestone), de-risking near-term operations and enabling continued development of its pipeline.

Rocket Pharmaceuticals borrowed $150 million from Hercules Capital in a structured deal where it gets money now and more money if it hits clinical or FDA approval goals, giving the company cash runway through at least 2030.